Trailing Dividend / Share
$0.00
Stoke Therapeutics, Inc. (STOK) Dividend History
Income profile from 2017 to 2024 with payout safety and yield-on-cost trend
Dividend Yield
N/A
Payout Ratio
N/A
Unknown
Dividend Streak
0 years
3-Second Income Check
Safety
Payout ratio data not available yet.
Consistency
0 straight years of dividend increases.
Income Trend
Yield on cost trend needs more history.
Dividend Scorecard
Yield & Income
Dividend YieldN/A
Trailing DPS$0.00
FrequencyN/A
Payments / 12M0
Payout Safety
Earnings PayoutN/A
Earnings SafetyUnknown
FCF PayoutN/A
FCF SafetyUnknown
Piotroski F-Score4/9
Growth
Growth Streak0 years
3Y CAGRN/A
5Y CAGRN/A
Yield on Cost (5Y)N/A
YOC Trendunknown
Total Returns
Buyback Yield0.0%
Total Shareholder Yield0.0%
1Y Total Return363.8%
5Y Total Return-40.4%
Estimated $10K growth (return + dividends):
5Y ago$5,95510Y ago$14,23920Y ago$14,239
Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). Different time windows can produce different outcomes depending on market regime and entry point.
Dividend History
No dividend payment history available
This company has not paid dividends during the available data period.
Dividend Analysis
Payout Safety
Stoke Therapeutics, Inc. has limited earnings payout data (Unknown).
Piotroski F-Score: 4/9 — moderate financial health.
Growth Track Record
STOK does not have a current streak of consecutive dividend increases.
Total Shareholder Returns
Beyond cash dividends, STOK returns capital through share repurchases. The combined picture: 0.0% total shareholder yield.
Income Trend & Total Return
The 5-year total return is -40.4%.
DRIP Growth
A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $14,239 today.
Annual Dividend History
8 years of dividend data
GrowthDecline
| Year | DPS | YoY | Pmts | EPS | Payout | Coverage | YOC |
|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | — | 0 | $-1.65 | — | — | — |
| 2023 | $0.00 | — | 0 | $-2.38 | — | — | — |
| 2022 | $0.00 | — | 0 | $-2.60 | — | — | — |
| 2021 | $0.00 | — | 0 | $-2.34 | — | — | — |
| 2020 | $0.00 | — | 0 | $-1.56 | — | — | — |
| 2019 | $0.00 | — | 0 | $-1.59 | — | — | — |
| 2018 | $0.00 | — | 0 | $-0.53 | — | — | — |
| 2017 | $0.00 | — | 0 | $-0.24 | — | — | — |
See STOK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STOK Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare STOK vs AGIO
See how STOK stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
How much dividend does STOK pay per share?
Stoke Therapeutics, Inc. (STOK) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made quarterly.
When is STOK's next ex-dividend date?
STOK's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. STOK typically pays dividends quarterly.
Is STOK's dividend safe?
STOK's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The dividend history does not yet show a prolonged growth streak.
How many years has STOK increased its dividend?
STOK has not maintained a consecutive growth streak recently. The 5-year dividend CAGR is N/A.
How often does STOK pay dividends?
Stoke Therapeutics, Inc. pays dividends quarterly. The trailing 12-month total is N/A per share. Dividend data on this page covers 7+ years from 2017 to 2024.
How much would $10,000 invested in STOK grow with dividend reinvestment?
With dividends reinvested (DRIP), $10,000 invested in STOK five years ago would be worth approximately $5,955 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.
What is STOK's yield on cost for long-term holders?
STOK's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.